PDF(Pubmed)
Abstract：
Lifestyle interventions can prevent type 2 diabetes (T2DM). However, some individuals do not experience anticipated improvements despite weight loss. Biomarkers to identify such individuals at early stages are lacking. Insulin-like growth factor 1 (IGF- 1) and Insulin-like growth factor binding protein 1(IGFBP-1) were shown to predict T2DM onset in prediabetes. We assessed whether these markers also predict the success of lifestyle interventions, thereby possibly guiding personalized strategies. We analyzed the fasting serum levels of IGF-1, IGFBP-1, and Insulin-like growth factor binding protein 2 (IGFBP-2) in relation to changes in metabolic and anthropometric parameters, including intrahepatic lipids (IHLs) and visceral adipose tissue (VAT) volume, measured by magnetic resonance imaging (MRI), in 345 participants with a high risk for prediabetes (54% female; aged 36-80 years). Participants were enrolled in three randomized dietary intervention trials and assessed both at baseline and one year post-intervention. Statistical analyses were performed using IBM SPSS Statistics (version 28), and significance was set at p < 0.05. Within the 1-year intervention, overall significant improvements were observed. Stratifying individuals by baseline IGF-1 and IGFBP-1 percentiles revealed significant differences: higher IGF-1 levels were associated with more favorable changes compared to lower levels, especially in VAT and IHL. Lower baseline IGFBP-1 levels were associated with greater improvements, especially in IHL and 2 h glucose. Higher bioactive IGF-1 levels might predict better metabolic outcomes following lifestyle interventions in prediabetes, potentially serving as biomarkers for personalized interventions.
摘要：
生活方式干预可以预防2型糖尿病（T2DM）。然而,尽管体重减轻，但有些人没有预期的改善。缺乏在早期阶段鉴定此类个体的生物标志物。胰岛素样生长因子1（IGF-1）和胰岛素样生长因子结合蛋白1（IGFBP-1）显示可预测糖尿病前期的T2DM发病。我们评估了这些标志物是否也能预测生活方式干预的成功，从而可能指导个性化策略。我们分析了IGF-1，IGFBP-1和胰岛素样生长因子结合蛋白2（IGFBP-2）的空腹血清水平与代谢和人体测量参数变化的关系。包括肝内脂质（IHL）和内脏脂肪组织（VAT）体积，通过磁共振成像（MRI）测量，在345名糖尿病前期风险较高的参与者中（54％为女性；年龄36-80岁）。参与者参加了三项随机饮食干预试验，并在基线和干预后一年进行了评估。使用IBMSPSSStatistics(28版)进行统计分析，并且显著性设定为p<0.05。在为期一年的干预中，观察到总体显著改善.通过基线IGF-1和IGFBP-1百分位数对个体进行分层显示出显着差异：与较低水平相比，较高的IGF-1水平与更有利的变化相关。特别是在增值税和国际人道主义法方面。较低的基线IGFBP-1水平与较大的改善相关，特别是在IHL和2h葡萄糖中。更高的生物活性IGF-1水平可能预测糖尿病前期生活方式干预后更好的代谢结果。可能作为个性化干预的生物标志物。
